Literature DB >> 10953946

Genetic hemochromatosis: detection, management, and population screening.

J S Dooley1, A P Walker.   

Abstract

Genetic hemochromatosis (GH) is an inherited disease that results in iron overload, and, if untreated, causes irreversible organ damage. Knowledge and understanding of the early features of the condition, often nonspecific, and of the diagnostic route are necessary to detect iron overload and diagnose GH before irremedial damage has been done. Genetic testing now plays an important role in diagnosis. Management of the patient with established GH centers on venesection to return body iron levels to normal, treatment of the complications of GH, and family screening for GH. Population screening for GH, the ideal strategy to prevent any morbidity from iron overload, has not yet been accepted by public health professionals, largely because of the lack of data on the disease penetrance in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10953946     DOI: 10.1089/10906570050114777

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  3 in total

1.  Changes in exercise capacity in subjects with cardiac asymptomatic hereditary hemochromatosis during a follow-up after 5 yrs.

Authors:  Yukitaka Shizukuda; Kevin P Smith; Dorothy J Tripodi; Ross Arena; Yu-Ying Yau; Charles D Bolan; Myron A Waclawiw; Susan F Leitman; Douglas R Rosing
Journal:  Am J Phys Med Rehabil       Date:  2012-05       Impact factor: 2.159

2.  Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity.

Authors:  Yukitaka Shizukuda; Dorothy J Tripodi; Gloria Zalos; Charles D Bolan; Yu-Ying Yau; Susan F Leitman; Myron A Waclawiw; Douglas R Rosing
Journal:  Am J Cardiol       Date:  2011-12-22       Impact factor: 2.778

3.  Prevalence of 845G>A HFE mutation in Slavic populations: an east-west linear gradient in South Slavs.

Authors:  Grazyna Adler; Jeremy S Clark; Beata Łoniewska; Andrzej Ciechanowicz
Journal:  Croat Med J       Date:  2011-06       Impact factor: 1.351

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.